The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 heads for best weekly performance in 9 months

Thu, 24th Oct 2019 09:33

* FTSE 100 up 0.9%, FTSE 250 down 0.1%
* AstraZeneca biggest boost to main index
* RBS slides after reporting Q3 loss
* EU decision on Brexit extension awaited

(Adds company news, updates share moves)
By Muvija M and Shashwat Awasthi
Oct 24 (Reuters) - London's exporter-heavy FTSE 100 jumped
along with its European counterparts on strong French
manufacturing data, while a sharp rise for AstraZeneca after a
2019 forecast upgrade and a slide in sterling amid Brexit woes
also lent support.
The blue-chip index climbed 0.9% to a near one-month
high, taking home gains for the fourth consecutive session and
outshining the European benchmark.
A sell-off in the pound ahead of the European Union's
decision on whether to grant Britain another Brexit extension
and amid risks of a possible general election led the
domestically focussed FTSE 250 0.1% lower.
The past two weeks have taken UK shares from pillar to post
with major Brexit developments including Prime Minister Boris
Johnson striking a new Brexit deal with the bloc and lawmakers
at home forcing his hand into asking for another extension to
the divorce.
Reflecting the anxiety ahead of EU's decision on the way
forward, a sub-index of homebuilders - a sector
considered among most vulnerable to the British economy - dipped
1% on its fourth straight session in the red.
UK blue-chips, on the other hand, accelerated early gains as
a weakening in the local currency boosted dollar earners in the
index including GlaxoSmithKline Plc and HSBC Holdings
Plc .
The bourse was already cheery after a survey showed French
business activity picked up more than expected in October.

'U.S.-CHINA AND BREXIT IN LIMBO'
The FTSE 100, whose components rake in more than two-thirds
of their earnings in U.S. dollars, is on course for its best
weekly performance since early February, as uncertainties over
the course of UK's EU departure have dented the value of
sterling.
AstraZeneca Plc contributed to nearly one-third of
the gains for FTSE 100 after the pharmaceutical firm raised its
annual product sales forecast for the second time this year. The
stock jumped nearly 6% on its best day in three months.

Analytics and decision tools provider Relx Plc and
industrial software company Aveva Group Plc added 4% and
5%, respectively, following trading updates.
"There's not been a huge catalyst for markets this week.
Earnings are largely topping beaten-down estimates. U.S.-China
and Brexit are in limbo," Markets.com analyst Neil Wilson said.
On the other end of the spectrum was Royal Bank of Scotland
Group Plc that skidded 3.3% as it swung to a
third-quarter loss due to a fresh 900 million pound provision to
settle mis-selling claims.
Woodford Patient Capital Trust Plc , formerly run by
once-star money manager Neil Woodford, surged 25% as the company
appointed asset manager Schroders Plc as its new
portfolio manager.
Metro Bank Plc jumped 11.5%, despite a grim
third-quarter earnings report, with a trader saying retail
investors saw a buying opportunity after the troubled lender's
CEO hinted that the company could consider takeover offers.


(Reporting by Muvija M and Shashwat Awasthi in Bengaluru;
Editing by Shounak Dasgupta and Lisa Shumaker)


More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.